24.08.2018 • News

South Korea’s S-Oil Mulls Cracker Complex

South Korea’s S-Oil Mulls Cracker Complex (c) S-Oil
South Korea’s S-Oil Mulls Cracker Complex (c) S-Oil

South Korean oil refiner and aromatics producer S-Oil, majority owned by Saudi Aramco, is looking into the feasibility of building a mixed-feed 1.5 million t/y cracker and downstream units.

The project is part of the company’s second-phase investment program to expand its petrochemical business. S-Oil expects to invest more than 5 trillion South Korean won ($4.4 billion) in the project by 2023.

The steam cracker will produce ethylene from naphtha and off-gas burned as fuel in the refinery, which S-Oil said will give the company an added advantage over feedstock sourcing and cost competitiveness. Downstream olefin derivatives including PE and PP will form part of the complex’s product slate.

S-Oil intends to build the complex on a 400,000m2 site that it purchased from Hyundai Heavy Industries near its oil refinery in Onsan, which the company said will secure high economics and operational efficiency.

The Seoul-headquartered company said it is confident that the project will put the company in a better position to navigate the rapid changes in the business environment brought on by shale oil and electric vehicles, among others.

Under a recent 4.8 trillion won diversification program, S-Oil invested in a residue upgrade and olefins complex at Ulsan, which included gasoline and methyl-tert-butyl ether plants and an alkylation unit. The residue fluid catalytic converter produces 600,000 t/y of propylene,   feeding plants producing 405,000 t/year PP and 300,000 t/y propylene oxide.

S-Oil is also a major producer of paraxylene, with a total capacity of 1.85 million t/y.

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read